NCT06223542
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Indolent Non-hodgkin Lymphoma, +8 more
- Locations
-
- National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
Clinical trial condition
Advanced Lymphoma
Explore clinical trials studying Advanced Lymphoma. Study availability and eligibility vary by location and protocol.
39 public trials
4 recruiting studies
Advanced Lymphoma trial results
Recruiting
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
NCT05969860
- Conditions
- Advanced Anal Carcinoma, Advanced Appendix Carcinoma, Advanced Basal Cell Carcinoma, +57 more
- Locations
-
- Mayo Clinic in Florida Jacksonville, Florida, United States
- Altru Cancer Center Grand Forks, North Dakota, United States
NCT04999384
- Conditions
- Advanced Lymphoma, Advanced Solid Tumor
- Locations
-
- Hackensack University Medical Center Hackensack, New Jersey, United States
- Montefiore Einstein Cancer Center The Bronx, New York, United States
- Prisma Health Institute for Translational Oncology Research Greenville, South Carolina, United States
- Next Virginia Fairfax, Virginia, United States
NCT05833893
- Conditions
- Advanced Lymphoma, Lymphoma, Lymphoma, Extranodal NK-T-Cell, +6 more
- Locations
-
- ChinaPLAGH Beijing, Haidian, China
Active, not recruiting
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
NCT04439253
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
- Locations
-
- ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States
Active, not recruiting
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
NCT06308822
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
- Locations
-
- ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States
Active, not recruiting
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
NCT06303167
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
- Locations
-
- ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States
Active, not recruiting
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
NCT04439136
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
- Locations
-
- ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States
Active, not recruiting
Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)
NCT06390852
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
- Locations
-
- ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States
Active, not recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060
- Conditions
- Adenocarcinoma, Adnexal Diseases, Advanced Lymphoma, +138 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- Thomas Hospital Fairhope, Alabama, United States
- Mobile Infirmary Medical Center Mobile, Alabama, United States
- University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States